DE-THE-LYCRA-COMPANY
1.6.2022 11:02:07 CEST | Business Wire | Press release
The LYCRA Company , a global leader in developing innovative fiber and technology solutions for the textile and apparel industry, will join a panel discussion at the inaugural United Nations Conscious Fashion and Lifestyle Network Annual Meeting taking place at the United Nations Headquarters in New York City on June 2.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005251/en/
With its recent commercialization of COOLMAX® and THERMOLITE® fibers made from 100% textile waste, The LYCRA Company is uniquely positioned to participate in the discussion titled Responsible Consumption and Production: Designing for Our Times . Jean Hegedus, sustainability director, The LYCRA Company, will share her perspective on how the company is scaling recycling solutions to help address the challenge of textile waste.
The meeting will welcome United Nations Conscious Fashion and Lifestyle Network advisory committee members and registered partnerships by industry stakeholders, media, Governments and United Nations system entities to highlight actions, solutions, and progress from the fashion and lifestyle sectors to advance sector engagement in the implementation of the Sustainable Development Goals adopted by the United Nations Member States in 2015. Discussions will focus on confronting the climate crisis, achieving gender equality throughout the value chain, and ensuring a resilient post-pandemic recovery.
“The LYCRA Company recognizes that the journey towards a more sustainable future is a collective effort across the industry,” said Kerry Bannigan, executive director, Fashion Impact Fund. “We are thrilled to have them join our first annual meeting to discuss solutions that will accelerate the fashion and lifestyle sector’s implementation of the Sustainable Development Goals.”
As the apparel industry looks to rapidly develop solutions for a circular economy, The LYCRA Company is focused on a variety of fiber and fabric innovations that reduce or divert waste, keeping materials in use and out of landfills. The company’s EcoMade family of recycled offerings includes LYCRA® , COOLMAX® and THERMOLITE® fibers made from both pre- and post-consumer waste. The LYCRA Company invites the industry to Keep in the Loop with LYCRA to learn about its latest sustainable innovations and circularity advancements, while also promoting collaboration.
The United Nations Conscious Fashion and Lifestyle Network’s inaugural annual meeting is co-convened by the United Nations Office for Partnerships and the Fashion Impact Fund.
Spokesperson Biography:
Jean Hegedus is the sustainability director for The LYCRA Company. Ms. Hegedus has over 35 years of experience in the textile industry, working first with The DuPont Company, and then INVISTA, before moving to The LYCRA Company in 2019. Over the course of her career, she has held a variety of positions in public affairs, marketing, licensing and branding. She began working in the denim segment in 2007, bringing several important innovations to market, including LYCRA® XFIT, LYCRA® dualFX® , LYCRA® BEAUTY, and LYCRA® EcoMade technologies. It was also her work within the denim segment that heightened her awareness of the need for more sustainable solutions, and in July of 2019, she was appointed sustainability director for The LYCRA Company. Ms. Hegedus has a master’s degree in communications from the University of Delaware.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA® , LYCRA HyFit® , LYCRA® T400® , COOLMAX® , THERMOLITE® , ELASPAN® , SUPPLEX® , and TACTEL® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA® is a trademark of The LYCRA Company.
About the United Nations Conscious Fashion and Lifestyle Network
The Conscious Fashion and Lifestyle Network is a United Nations (UN) hosted online platform for industry stakeholders, media, Governments, and UN system entities. The network showcases and enables collaborations that accelerate the implementation of the Sustainable Development Goals. The United Nations Conscious Fashion and Lifestyle Network is a joint initiative of the United Nations Office for Partnerships, the Division for Sustainable Development Goals - United Nations Department of Economic and Social Affairs, and the Fashion Impact Fund. The leading entities of the network convene periodic events aligned with key meetings on the UN calendar and publish reports on the network’s achievements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005251/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom